Aten Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 25-12-2024
- Paid Up Capital ₹ 1.80 M
as on 25-12-2024
- Company Age 11 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 66.02%
(FY 2022)
- Profit 32.45%
(FY 2022)
- Ebitda 20.12%
(FY 2022)
- Net Worth -3.36%
(FY 2022)
- Total Assets -7.00%
(FY 2022)
About Aten Biotech
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.80 M, as per Ministry of Corporate Affairs (MCA) records.
Aditya Kulkarni and Arun Papaiah serve as directors at the Company.
- CIN/LLPIN
U01403KA2013PTC069439
- Company No.
069439
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Jun 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Aten Biotech Private Limited offer?
Aten Biotech Private Limited offers a wide range of products and services, including Fresh Flowers, Plants & Trees, Garden Plant, Indoor Plants, Hybrid Plant, Ornamental Plants, Philodendron Plant, Plant Tissue Culture, Banana Tissue Culture Plants, Outdoor Plant, Agar Plant.
Who are the key members and board of directors at Aten Biotech?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arun Papaiah  | Managing Director | 01-Jun-2013 | Current |
| Aditya Kulkarni | Managing Director | 01-Jun-2013 | Current |
Board Members(0)
| Name | Designation | Appointment Date | Status |
|---|
Financial Performance of Aten Biotech.
Aten Biotech Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 66.02% increase. The company also saw a substantial improvement in profitability, with a 32.45% increase in profit. The company's net worth dipped by a decrease of 3.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aten Biotech?
In 2022, Aten Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Aten Porus Lifesciences Private LimitedActive 11 years 5 monthsAditya Kulkarni and Arun Papaiah are mutual person
- Avammune Lifesciences Private LimitedActive 2 months 1 day
Aditya Kulkarni and Arun Papaiah are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aten Biotech?
Aten Biotech has a workforce of 1 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aten Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aten Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
